Iovance Biotherapeutics Explained

Iovance Biotherapeutics, Inc.
Former Name:	Lion Biotechnologies, Inc.
Type:	Public
Predecessors:	-->
Successors:	-->
Areas Served:	-->
Key People:	Steven Rosenberg
Owners:	-->
Num Employees:	319 (December 31, 2021)

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.^{[1] [2]}

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.^[3]

In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.^[4]

See also

• Kite Pharma

Notes and References

1. News: Garber. Ken. 7 August 2019. Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up. Nature Biotechnology. 14 August 2019.
2. News: Adelman. Jacob. 29 May 2019. New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance. The Philadelphia Inquirer. 14 August 2019.
3. Web site: Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies. 2013-07-25. www.businesswire.com. en. 2020-01-17.
4. Mullard . Asher . 2024-02-19 . FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers . Nature Reviews Drug Discovery . en . 10.1038/d41573-024-00035-1. 38374249 .